Measles Vaccination in Presence of Measles Antibody May Enhance Child Survival

In trials of early two-dose measles vaccination (MV), with the first dose being given before 9 months of age, vaccination in the presence of maternal antibody reduced mortality 2- to 3-fold compared with MV in the presence of no measles antibody. We tested this finding in two historical studies in w...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pediatrics 2020-02, Vol.8, p.20-20
Main Authors: Benn, Christine S, Martins, Cesário L, Andersen, Andreas, Fisker, Ane B, Whittle, Hilton C, Aaby, Peter
Format: Article
Language:English
Subjects:
child mortality in Africa
heterologous (non-specific) effects of vaccines
maternal antibodies (matab)
measles
Pediatrics
vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In trials of early two-dose measles vaccination (MV), with the first dose being given before 9 months of age, vaccination in the presence of maternal antibody reduced mortality 2- to 3-fold compared with MV in the presence of no measles antibody. We tested this finding in two historical studies in which the children had received one dose of MV. We used data from a surveillance study of seroconversion after standard-titer MV (Schwarz strain) (Study 1) and a trial of early medium-titer MV (Edmonston-Zagreb strain) in which a pre-vaccination blood sample had been collected (Study 2). Both studies had control children, who were enrolled under similar conditions, but did not receive effective MV. Study 1 was a natural experiment where all children measles vaccinated during 1 month did not seroconvert and had therefore received an ineffective vaccine. In Study 2, the controls were randomized to an inactivated polio vaccine (IPV). We compared mortality for children with undetectable levels of measles antibody (
ISSN:2296-2360
2296-2360
DOI:10.3389/fped.2020.00020